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TuberculosisA B S T R A C T
Objective/background: Mycobacterium tuberculosis is an obligate pathogenic bacterial species in
the family Mycobacteriaceae and the causative agent of most tuberculosis (TB) cases. Until
today, the only approved TB vaccine is Bacille Calmette Guerin (BCG), which has been used
since 1921. While BCG provides fairly effective protection for infants and young children,
its efficacy in adults is variable around the world. This could be due to several parameters
including strains of the vaccine and exposure of individuals to different environmental bac-
terial infections. The situation is complicated by the emergence of multidrug resistant
strains of M. tuberculosis. This urged the demand to develop new improved vaccines and
immunotherapies against TB. Development of nonpathogenic recombinant constructs
delivering M. tuberculosis-specific antigenic proteins provides the chance to evaluate candi-
dates to be included in diagnostic tools and preventive vaccines. In our study, we are intro-
ducing someof themajorM. tuberculosis genes in Escherichia coli andMycobacterium smegmatis.
Methods: DNA corresponding to the genes Rv3891, Rv3020, Rv0287, Rv3875, Rv3874, Rv3872,
Rv2346c, and Rv3619 were PCR-amplified from M. tuberculosis genomic DNA and visualized
on gel electrophoresis at the expected DNA size. Products were subsequently ligated to the
plasmid pGEMTeasy and used to transformTOP10 E. coli. Transformed colonieswere selected
on appropriate media. At the second stage, genes-DNAwere subcultured in expression vec-
tors pDE22 and pGESTH1; the recombinant plasmidswere finally used to transform.M. smeg-
matis and E. coli, respectively. Expression of proteins in E. coli was confirmed by Western
blotting and in M. smegmatis by reverse transcriptase polymerase chain reaction (RT-PCR).
Results: Amplified genes were successfully cloned and transformed in E. coli and
M. smegmatis. Colonies of recombinant bacteria were detected on appropriate media.
Western blotting and RT-PCR confirmed the expression of our corresponding proteins in both
the bacterial vehicles.
Conclusion: Positive results of cloning and expression suggest that the constructed clones are
ready tools for further assessment of their immunogenicity and can be included in improved
diagnostic tools and vaccines against TB.expressing
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